Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKTSNASDAQ:AMRN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTSAkoustis Technologies$0.07$0.03▼$1.19$10.54M1.9139.87 million shs118.70 million shsAMRNAmarin$15.71-1.2%$11.79$7.08▼$17.18$325.31M0.7181,128 shs112,529 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTSAkoustis Technologies0.00%0.00%0.00%0.00%-72.75%AMRNAmarin0.00%+25.28%+34.50%+78.44%+12.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKTSAkoustis TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AAMRNAmarin0.7276 of 5 stars0.55.00.00.03.20.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTSAkoustis Technologies 0.00N/AN/AN/AAMRNAmarin 1.00Sell$12.00-23.62% DownsideCurrent Analyst Ratings BreakdownLatest AKTS and AMRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025AMRNAmarinThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSell ➝ Sell$7.00 ➝ $12.004/17/2025AMRNAmarinThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$20.00 ➝ $7.00(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTSAkoustis Technologies$27.38M0.00N/AN/A($0.46) per share0.00AMRNAmarin$228.61M1.42N/AN/A$23.62 per share0.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTSAkoustis Technologies-$167.95MN/A0.00N/AN/A-524.47%-584.18%-166.76%N/AAMRNAmarin-$82.18M-$3.64N/AN/AN/A-41.07%-17.21%-12.16%7/30/2025 (Estimated)Latest AKTS and AMRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025AMRNAmarin-$0.06-$0.04+$0.02-$0.04$50.75 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTSAkoustis TechnologiesN/AN/AN/AN/AN/AAMRNAmarinN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTSAkoustis Technologies1.000.320.28AMRNAmarinN/A3.532.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTSAkoustis Technologies28.84%AMRNAmarin22.25%Insider OwnershipCompanyInsider OwnershipAKTSAkoustis Technologies3.30%AMRNAmarin3.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKTSAkoustis Technologies210154.59 million149.49 millionOptionableAMRNAmarin36020.71 million20.02 millionOptionableAKTS and AMRN HeadlinesRecent News About These CompaniesWaterfront Wealth Inc. Has $1.13 Million Stock Holdings in Amarin Corporation PLC (NASDAQ:AMRN)June 29 at 7:59 AM | marketbeat.comWhat is Zacks Research's Estimate for Amarin Q3 Earnings?June 29 at 2:16 AM | marketbeat.comZacks Research Has Bullish Forecast for Amarin Q3 EarningsJune 28 at 2:07 AM | americanbankingnews.comAmarin (AMRN) Soars 27.3%: Is Further Upside Left in the Stock? - NasdaqJune 27 at 5:06 PM | nasdaq.comBest Momentum Stock to Buy for June 27thJune 27 at 11:00 AM | zacks.comThe Goldman Sachs Group Forecasts Strong Price Appreciation for Amarin (NASDAQ:AMRN) StockJune 27 at 2:29 AM | americanbankingnews.comAmarin (NASDAQ:AMRN) Given New $12.00 Price Target at The Goldman Sachs GroupJune 25, 2025 | marketbeat.comAmarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EUJune 25, 2025 | zacks.comAmarin (AMRN) Soars 27.3%: Is Further Upside Left in the Stock?June 25, 2025 | zacks.comAmarin, Recordati Ink Exclusive License, Supply Deal to Commercialize VazkepaJune 24, 2025 | marketwatch.comAmarin sells heart pill Vascepa's rights in Europe to Recordati amid restructuring bidJune 24, 2025 | fiercepharma.comFAmarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in EuropeJune 24, 2025 | finance.yahoo.comAmarin Stock Surges 11% After $25 Million Licensing Deal with RecordatiJune 24, 2025 | msn.comAmarin inks licensing deal with Recordati for lead drug VazkepaJune 24, 2025 | msn.comRECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPEJune 24, 2025 | globenewswire.comAmarin (NASDAQ:AMRN) Shares Cross Above Two Hundred Day Moving Average - Should You Sell?June 24, 2025 | marketbeat.comAmarin (AMRN) Now Trades Above Golden Cross: Time to Buy?June 16, 2025 | zacks.comIs Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?June 16, 2025 | zacks.comAmarin (NASDAQ:AMRN) Stock Passes Above Two Hundred Day Moving Average - Here's What HappenedJune 14, 2025 | marketbeat.comAmarin (AMRN) Upgraded to Strong Buy: What Does It Mean for the Stock?June 10, 2025 | zacks.comBest Momentum Stocks to Buy for June 10thJune 10, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKTS and AMRN Company DescriptionsAkoustis Technologies NASDAQ:AKTSAkoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., designs, develops, manufactures, and sells radio frequency (RF) filter products for the mobile wireless device industry in the United States, Asia, Europe, and internationally. It operates through Foundry Fabrication Services and RF Filters segments. The Foundry Fabrication Services segment provides engineering review and backend packaging services. Its RF Filters segment sells amplifier and filter products. It offers RF filters for mobile wireless devices, such as smartphones and tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, and military and defense applications. The company was founded in 2013 and is headquartered in Huntersville, North Carolina.Amarin NASDAQ:AMRN$15.71 -0.19 (-1.19%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$15.81 +0.10 (+0.64%) As of 06/27/2025 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
